-DOCSTART- -X- O
Alphavirus -X- _ O
vectors -X- _ O
have -X- _ O
demonstrated -X- _ O
high -X- _ O
levels -X- _ O
of -X- _ O
transient -X- _ O
heterologous -X- _ O
gene -X- _ O
expression -X- _ O
both -X- _ O
in -X- _ O
vitro -X- _ O
and -X- _ O
in -X- _ O
vivo -X- _ O
and -X- _ O
, -X- _ O
therefore -X- _ O
, -X- _ O
possess -X- _ O
attractive -X- _ O
features -X- _ O
for -X- _ O
vaccine -X- _ O
development. -X- _ O
The -X- _ O
most -X- _ O
commonly -X- _ O
used -X- _ O
delivery -X- _ O
vectors -X- _ O
are -X- _ O
based -X- _ O
on -X- _ O
three -X- _ O
single-stranded -X- _ O
encapsulated -X- _ O
alphaviruses -X- _ O
, -X- _ O
namely -X- _ O
Semliki -X- _ O
Forest -X- _ O
virus -X- _ O
, -X- _ O
Sindbis -X- _ O
virus -X- _ O
and -X- _ O
Venezuelan -X- _ O
equine -X- _ O
encephalitis -X- _ O
virus. -X- _ O
Alphavirus -X- _ O
vectors -X- _ O
have -X- _ O
been -X- _ O
applied -X- _ O
as -X- _ O
replication-deficient -X- _ O
recombinant -X- _ O
viral -X- _ O
particles -X- _ O
and -X- _ O
, -X- _ O
more -X- _ O
recently -X- _ O
, -X- _ O
as -X- _ O
replication-proficient -X- _ O
particles. -X- _ O
Moreover -X- _ O
, -X- _ O
in -X- _ O
vitro -X- _ O
transcribed -X- _ O
RNA -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
layered -X- _ O
DNA -X- _ O
vectors -X- _ O
have -X- _ O
been -X- _ O
applied -X- _ O
for -X- _ O
immunization. -X- _ O
A -X- _ O
large -X- _ O
number -X- _ O
of -X- _ O
highly -X- _ O
immunogenic -X- _ O
viral -X- _ O
structural -X- _ O
proteins -X- _ O
expressed -X- _ O
from -X- _ O
alphavirus -X- _ B-Outcome
vectors -X- _ I-Outcome
have -X- _ I-Outcome
elicited -X- _ I-Outcome
strong -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ I-Outcome
multispecies -X- _ I-Outcome
animal -X- _ I-Outcome
models. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
immunization -X- _ B-Outcome
studies -X- _ I-Outcome
have -X- _ I-Outcome
demonstrated -X- _ I-Outcome
robust -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
challenges -X- _ I-Outcome
with -X- _ I-Outcome
lethal -X- _ I-Outcome
doses -X- _ I-Outcome
of -X- _ I-Outcome
virus -X- _ I-Outcome
in -X- _ I-Outcome
rodents -X- _ I-Outcome
and -X- _ I-Outcome
primates. -X- _ I-Outcome
Similarly -X- _ I-Outcome
, -X- _ I-Outcome
vaccination -X- _ I-Outcome
with -X- _ I-Outcome
alphavirus -X- _ I-Outcome
vectors -X- _ I-Outcome
expressing -X- _ I-Outcome
tumor -X- _ I-Outcome
antigens -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
prophylactic -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
challenges -X- _ I-Outcome
with -X- _ I-Outcome
tumor-inducing -X- _ I-Outcome
cancerous -X- _ I-Outcome
cells. -X- _ I-Outcome
As -X- _ O
certain -X- _ O
alphaviruses -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
Chikungunya -X- _ O
virus -X- _ O
, -X- _ O
have -X- _ O
been -X- _ O
associated -X- _ O
with -X- _ O
epidemics -X- _ O
in -X- _ O
animals -X- _ O
and -X- _ O
humans -X- _ O
, -X- _ O
attention -X- _ O
has -X- _ O
also -X- _ O
been -X- _ O
paid -X- _ O
to -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
vaccines -X- _ O
against -X- _ O
alphaviruses -X- _ O
themselves. -X- _ O
Recent -X- _ O
progress -X- _ O
in -X- _ O
alphavirus -X- _ O
vector -X- _ O
development -X- _ O
and -X- _ O
vaccine -X- _ O
technology -X- _ O
has -X- _ O
allowed -X- _ O
conducting -X- _ O
clinical -X- _ O
trials -X- _ O
in -X- _ O
humans -X- _ O
. -X- _ O

